Transdermal donepezil on the treatment of Alzheimer’s disease

References

• SmallGWRabinsPVBarryPPDiagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA199727816136313719343469
   PubMed Web of Science ®Google Scholar
• BryneGJTreatment of cognitive impairment in Alzheimer’s diseaseAustralian Journal of Hospital Pharmacy199828261266
   Google Scholar
• DooleyMLambHMDonepezil: a review of its use in Alzheimer’s diseaseDrugs Aging200016319922610803860
   PubMed Web of Science ®Google Scholar
• ChanALChienYWJin LinSTransdermal delivery of treatment for Alzheimer’s disease: development, clinical performance and future prospectsDrugs Aging200825976177518729547
   PubMed Web of Science ®Google Scholar
• CutlerNRSramekJJThe role of bridging studies in the development of cholinesterase inhibitors for Alzheimer’s diseaseCNS Drugs1998105355364
   Web of Science ®Google Scholar
• BrodatyHRealistic expectations for the management of Alzheimer’s diseaseEur Neuropsychopharmacol19999Suppl 2S43S5210332934
   PubMed Web of Science ®Google Scholar
• SchachterASDavisKLGuidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer’s diseaseCNS Drugs199911281288
   Web of Science ®Google Scholar
• GiacobiniECholinesterase inhibitors stabilize Alzheimer’s diseaseAnn N Y Acad Sci200092032132711193171
   PubMed Web of Science ®Google Scholar
• KurzAFarlowMLefevreGPharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a reviewInt J Clin Pract200963579980519392927
   PubMed Web of Science ®Google Scholar
• LamyPPThe role of cholinesterase inhibitors in Alzheimer’s diseaseCNS Drugs19941146165
   Web of Science ®Google Scholar
• SramekJJCutlerNRRecent developments in the drug treatment of Alzheimer’s diseaseDrugs Aging199914535937310408736
   PubMed Web of Science ®Google Scholar
• BlackSEDoodyRLiHDonepezil preserves cognition and global function in patients with severe Alzheimer diseaseNeurology200769545946917664405
   PubMed Web of Science ®Google Scholar
• Di StefanoAIannitelliALaserraSSozioPDrug delivery strategies for Alzheimer’s disease treatmentExpert Opin Drug Deliv20118558160321391862
   PubMed Web of Science ®Google Scholar
• TakedaMTanakaTOkochiMNew drugs for Alzheimer’s disease in JapanPsychiatry Clin Neurosci201165539940421851448
   PubMed Web of Science ®Google Scholar
• WinbladBJelicVLong-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitorsAlzheimer Dis Assoc Disord200418Suppl 1S2S815249842
   PubMed Web of Science ®Google Scholar
• JelicVDarreh-ShoriTDonepezil: a review of pharmacological characteristics and role in the management of Alzheimer diseaseClinical Medical Insights: Therapeutics20102771788
   Google Scholar
• BassilNGrossbergGTNovel regimens and delivery systems in the pharmacological treatment of Alzheimer’s diseaseCNS Drugs200923429330719374459
   PubMed Web of Science ®Google Scholar
• University of BirminghamAD2000 study [homepage on the Internet]Birmingham, UKUniversity of Birmingham Available from: http://www.ad2000.bham.ac.uk/Accessed May 30, 2012
   Google Scholar
• RogersSLFarlowMRDoodyRSMohsRFriedhoffLTA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study GroupNeurology19985011361459443470
   PubMed Web of Science ®Google Scholar
• WeyerGErzigkeitHKanowskiSIhlRHadlerDAlzheimer’s Disease Assessment Scale: reliability and validity in a multicenter clinical trialInt Psychogeriatr1997921231389309486
   PubMedGoogle Scholar
• TanakaTKazuiHMoriharaTSadikGKudoTTakedaMPost-marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer’s disease with behavioral and psychological symptoms of dementia (BPSD)Psychogeriatrics200883114123
   Web of Science ®Google Scholar
• Eisai IncComparison of 23 mg donepezil sustained release (SR) to 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer’s diseaseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2007 [updated April 25, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00478205. NLM identifier: NCT00478205Accessed April 25, 2011
   Google Scholar
• FarlowMRSallowaySTariotPNEffectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind studyClin Ther20103271234125120678673
   PubMed Web of Science ®Google Scholar
• For Eisai IncOpen-label extension study of 23 mg donepezil SR in patients with moderate to severe Alzheimer’s diseaseClinicalTrials gov [website on the Internet]Bethesda, MDClinicalTrialsgov, US National Library of Medicine2007 [updated May 16, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00566501. NLM identifier: NCT00566501Accessed October 28, 2011
   Google Scholar
• US Food and Drug Administration Aricept^® ODTs [document on the Internet]Silver Spring, MDUS Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020690s026,021720s003lbl.pdfAccessed. August 10, 2012
   Google Scholar
• SeltzerBDonepezil: an updateExpert Opin Pharmacother2007871011102317472546
   PubMed Web of Science ®Google Scholar
• FarlowMVelosoFMolineMSafety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s diseaseBMC Neurol2011115721612646
   PubMed Web of Science ®Google Scholar
• FarlowMRAlvaGMengXOlinJTA 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysisCurr Med Res Opin201026226326919929593
   PubMed Web of Science ®Google Scholar
• PrianoLGascoMRMauroATransdermal treatment options for neurological disorders: impact on the elderlyDrugs Aging200623535737516823990
   PubMed Web of Science ®Google Scholar
• ValiaKHRamarajuVSCore Tech Solutions, assigneeTransdermal methods and systems for treating Alzheimer’s diseaseUnited States patentUS 20080044461A12212008
   Google Scholar
• BhowmikDChiranjibBDChandiraMJayakarBSampathKPRecent advances in transdermal drug delivery systemInt J PharmTech Res2010216877
   Google Scholar
• OertelWRossJSEggertKAdlerGRationale for transdermal drug administration in Alzheimer diseaseNeurology2007694 Suppl 1S4S917646621
   PubMed Web of Science ®Google Scholar
• TannerTMarksRDelivering drugs by the transdermal route: review and commentSkin Res Technol200814324926019159369
   PubMed Web of Science ®Google Scholar
• Chanukya KumarGA review on transdermal therapeutics systemIJPT20113313671381
   Google Scholar
• MontagnaWParakkalPFThe Structure and Function of Skin3rd edNew YorkAcademic Press1974
   Google Scholar
• HolbroockKAWolffKThe structure and development of skinFitzpatrickTBEisenAZWolffKFreedbergIMAustenKFDermatology in General MedicineNew YorkMcGraw-Hill199397145
   Google Scholar
• BoninaFPPugliaCBarbuzziTIn vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenacEur J Pharm Sci200114212313411500258
   PubMed Web of Science ®Google Scholar
• GhoshTKPfisterWRTransdermal and topical delivery systems: an overview and future trendsGhoshTKPfisterWRYumSITransdermal and Topical Drug Delivery SystemsIllinoisInterpharm Press1997132
   Google Scholar
• NittiVWSandersSStaskinDRTransdermal delivery of drugs for urologic applications: basic principles and applicationsUrology200667465766416618554
   PubMed Web of Science ®Google Scholar
• BosJDMeinardiMMThe 500 Dalton rule for the skin penetration of chemical compounds and drugsExp Dermatol20009316516910839713
   PubMed Web of Science ®Google Scholar
• MbahCJUzorPFOmejeEOPerspectives on transdermal drug deliveryJ Chem Pharm Res201133680700
   Google Scholar
• ThevisMWilkensFGeyerHSchänzerWDetermination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposesRapid Commun Mass Spectrom200620223393340217051614
   PubMed Web of Science ®Google Scholar
• XiaZJiangXMuXChenHImprovement of microemulsion electrokinetic chromatography for measuring octanol-water partition coefficientsElectrophoresis200829483584218203250
   PubMed Web of Science ®Google Scholar
• ChoiJChoiMKChongaSChungSJShimaCKKimDDEffect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluationInt J Pharm20124221–2839022037444
   PubMed Web of Science ®Google Scholar
• Teikoku Pharma USAStudy in elderly Alzheimer’s subjects 3 consecutive 7-day applications of 350 mg DTP-Donepezil Transdermal Patch-System (DTP-System)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated June 15, 2012]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00916383. NLM identifier: NCT00916383Accessed November 3, 2011
   Google Scholar
• Eisai Co, LtdE2022 patch formulation single dose Phase I studyClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated August 11, 2011]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01253434. NLM identifier: NCT01253434Accessed August 11, 2011
   Google Scholar
• Eisai Co, LtdE2022 patch formulation multiple dose studyClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated May 30, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01450839Accessed May 30, 2012
   Google Scholar
• Dementia and Alzheimer’s Weekly [homepage on the Internet]Once-weekly transdermal patch formulationNew YorkAlzheimer’s Weekly LLC Available from: http://alzheimersweekly.com/content/testing-aricept-variationsAccessed August 10, 2012
   Google Scholar
• Eisai Co, LtdEisai amends license agreement with Teikoku Pharma USA for ARICEPT^® transdermal patch system [news release]TokyoEisai Co, Ltd2012 [April 20]. Available from: http://www.eisai.com/news/enews201217pdf.pdfAccessed May 21, 2012
   Google Scholar